EUVIMEDEUVIMED entdecken
Crossref

Sickle cell drug is withdrawn over safety concerns just months after rollout

Elisabeth Mahase

BMJ · 01.10.2024 · q2147

DOI: 10.1136/bmj.q2147 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BMJ, online erschienen am 01.10.2024. Verfasst von Elisabeth Mahase. Beteiligte Einrichtung: The BMJ. Hauptthemen laut MEDLINE: Antisickling Agents, Safety-Based Drug Withdrawals. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 6 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antisickling AgentsSafety-Based Drug WithdrawalsHumansAnemia, Sickle CellPyrazinesBenzaldehydesPyrazoles

Substanzen

Antisickling AgentsPyrazinesvoxelotorBenzaldehydesPyrazoles

Autor:innen und Institutionen

  • The BMJ.

Zitieren

APA

Mahase, E. (2024). Sickle cell drug is withdrawn over safety concerns just months after rollout. BMJ, q2147. https://doi.org/10.1136/bmj.q2147

Vancouver

Mahase E. Sickle cell drug is withdrawn over safety concerns just months after rollout. BMJ. 2024:q2147. doi:10.1136/bmj.q2147

BibTeX
@article{Mahase2024,
  author = {Mahase, Elisabeth},
  title = {Sickle cell drug is withdrawn over safety concerns just months after rollout},
  journal = {BMJ},
  year = {2024},
  pages = {q2147},
  doi = {10.1136/bmj.q2147}
}
Kostenlos starten →